Given the comments of Solagran management - that Ropren approval is "99% certain," we are all aware that approval has been priced into this stock. There is only one question that bugs me: how far will it fall if the Russian authorities request more data?
Probably not too far, but then it will be either time to partner with big pharma, or time for a capital raising.
Either one will result in further dilution of an already hefty 300 million market cap.
Just a warning not to trade this one. There is no upside to Ropren approval, so this is best digested from the sidelines. A capital raising will come at a significant discount to the market price.
- Forums
- ASX - By Stock
- ropren approval already priced in
Given the comments of Solagran management - that Ropren approval...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online